Pluristem Therapeutics Inc PSTI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:00 PM EST
5.22quote price arrow down-0.36 (-6.45%)
Volume
471,241
52 week range
2.82 - 13.29

...

Loading . . .

KEY STATS

  • Open5.75
  • Day High5.75
  • Day Low5.06
  • Prev Close5.58
  • 52 Week High13.29
  • 52 Week High Date04/24/20
  • 52 Week Low2.82
  • 52 Week Low Date03/12/20
  • Market Cap164.59M
  • Shares Out31.53M
  • 10 Day Average Volume0.55M
  • Dividend-
  • Dividend Yield-
  • Beta2.50
  • 1 Year % Change47.93

RATIOS/PROFITABILITY

  • EPS (TTM)-1.59
  • P/E (TTM)-3.29
  • Fwd P/E (NTM)-4.05
  • EBITDA (MRQ)-36.312M
  • ROE (MRQ)-128.59%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)100.00%
  • Net Margin (MRQ)-132,617.40%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Pluristem Therapeutics Inc News

There is no recent news for this security.

Latest PSTI News From Our Partners

QUOTE FINDER

Profile

MORE
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products...
Zalman Aberman
Chairman
Yaky Yanay
President
Chen Franco-Yehuda
Chief Financial Officer
Address
Matam Advanced Technology Park
Building No. 5
Haifa
3508409
Israel